Skip to main content

Redo Transcatheter Aortic Valve Replacement Safe, Effective

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

MONDAY, Sept. 11, 2023 -- Redo transcatheter aortic valve replacement (TAVR) procedures are as safe and effective as native TAVR in select patients, according to a study published online Aug. 31 in The Lancet.

Raj R. Makkar, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues assessed the safety and efficacy of redo TAVR in a national registry. The analysis included all consecutive patients in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (Nov. 9, 2011, to Dec. 30, 2022) who underwent TAVR with balloon-expandable valves in either failed transcatheter heart valves (redo TAVR; 1,320 patients) or native aortic valves (native TAVR; 349,271 patients).

The researchers found that the rates of procedural complications of redo TAVR were low (coronary compression or obstruction: 0.3 percent; intraprocedural death: 0.6 percent; conversion to open heart surgery: 0.5 percent) and overall similar to native TAVR. For death at 30 days (4.7 versus 4.0 percent) or one year (17.5 versus 19.0 percent) and stroke at 30 days (2.0 versus 1.9 percent) or one year (3.2 versus 3.5 percent), there were no significant differences between redo-TAVR and native-TAVR populations, respectively. At one year, redo TAVR reduced aortic valve gradients, although they were higher in the redo-TAVR group versus the native-TAVR group (15 versus 12 mm Hg). Rates of moderate or severe aortic regurgitation did not differ significantly between the redo-TAVR and native-TAVR groups at one year (1.8 versus 3.3 percent). Timing of redo TAVR (before or after one year of index TAVR) and index transcatheter valve type (balloon-expandable or non-balloon-expandable) did not significantly affect death or stroke after redo TAVR.

"Redo-TAVR with balloon-expandable valves might be a reasonable treatment for failed TAVR in selected patients," the authors write.

Edwards Lifesciences funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease

TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...

Statins Reduce CVD Risk in Adults Aged 75 to 85 and 85 Years and Older

TUESDAY, May 28, 2024 -- For patients aged 75 years and older, statin therapy is associated with a risk reduction in cardiovascular diseases (CVDs), according to a study published...

Fish Oil Beneficial for Reducing Risk for Cardiovascular Disease Progression

WEDNESDAY, May 22, 2024 -- The role of regular use of fish oil supplements varies for people with and without cardiovascular disease, according to a study published online May 21...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.